The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
Based on the PureTech Health plc stock forecast from 0 analysts, the average analyst target price for PureTech Health plc is not available over the next 12 months. PureTech Health plc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of PureTech Health plc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, PureTech Health plc’s stock price was USD 2.07. PureTech Health plc’s stock price has changed by -0.96% over the past week, -1.43% over the past month and -18.82% over the last year.
No recent analyst target price found for PureTech Health plc
No recent average analyst rating found for PureTech Health plc
Company Overview PureTech Health plc
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. Read Less
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal ...Read More
Frequently Asked Questions About PureTech Health plc (PTCHF) Stock
Stock Target Advisor's fundamental analysis for PureTech Health plc's stock is Slightly Bearish.
Unfortunately we do not have enough data on PTCHF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PTCHF's stock to indicate what its average analyst target is.
PTCHF stock's Price/Earning ratio is 236.00.
Our analysis grades PTCHF stock's Price / Earning ratio at F. This means that PTCHF stock's Price/Earning ratio is above 99% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this PTCHF may be a overvalued for its sector.
The last closing price of PTCHF's stock was USD 2.07.
The most recent market capitalization for PTCHF is USD 0.52B.
Unfortunately we do not have enough analyst data on PTCHF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains PureTech Health plc's stock.
As per our most recent records PureTech Health plc has 90 Employees.
PureTech Health plc's registered address is 6 Tide Street, Boston, MA, United States, 02210.
You can get more information about it from PureTech Health plc's website at https://www.puretechhealth.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About PureTech Health plc (PTCHF) Stock
Stock Target Advisor's fundamental analysis for PureTech Health plc's stock is Slightly Bearish.
Unfortunately we do not have enough data on PTCHF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PTCHF's stock to indicate what its average analyst target is.
PTCHF stock's Price/Earning ratio is 236.00.
Our analysis grades PTCHF stock's Price / Earning ratio at F. This means that PTCHF stock's Price/Earning ratio is above 99% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this PTCHF may be a overvalued for its sector.
The last closing price of PTCHF's stock was USD 2.07.
The most recent market capitalization for PTCHF is USD 0.52B.
Unfortunately we do not have enough analyst data on PTCHF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains PureTech Health plc's stock.
As per our most recent records PureTech Health plc has 90 Employees.
PureTech Health plc's registered address is 6 Tide Street, Boston, MA, United States, 02210.
You can get more information about it from PureTech Health plc's website at https://www.puretechhealth.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PTCHF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
